<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-047277</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infections in Spain: SMART 2003 study outcomes</dc:title>
<dc:description xml:lang="en">SMART (Study for Monitoring Antimicrobial Resistance Trends) is an ongoing global antimicrobial surveillance program focused on clinical isolates from intra-abdominal infections. The objective of this subanalysis was to assess antimicrobial susceptibility patterns among Enterobacteriaceae recovered at 13 participating Spanish sites during 2003. Antimicrobial susceptibility testing was performed using broth microdilution techniques according to the CLSI (formerly NCCLS) guidelines for MIC testing. The presence of extended-spectrum beta-lactamases        (ESBL) was confirmed in isolates with a MIC of ceftriaxone, ceftazidime, or cefepime &gt;2 mg/l by comparing cefepime MICs with and without clavulanate. A total of 981 Enterobacteriaceae recovered from 840 patients were tested, of which 398 (41%) were community-acquired. Escherichia coli was the most common isolate (571 isolates; 58%), followed by Klebsiella spp. (153; 16%), Enterobacter spp. (97; 10%), and Proteus spp. (63; 6%). A total of 191 isolates (19%) from 176 patients produced inducible beta-lactamases. The carbapenems and amikacin were the most consistently active agents against the Enterobacteriaceae (susceptibility &gt;99%). Resistance rates for ceftazidime, ciprofloxacin, and levofloxacin exceeded 10%. ESBLs were detected phenotypically in 61 (6%) isolates, being the most common E. coli (61%),        Klebsiella spp. (20%), and Enterobacter spp. (8%). Antimicrobial resistance among Enterobacteriaceae isolated from intra-abdominal infections is a problem in Spain. A significant proportion of inducible beta-lactamase and ESBL-producing Enterobacteriaceae causing intra-abdominal infection were acquired in the community. The carbapenems ertapenem, imipenem and meropenem and the aminoglycoside amikacin were highly active in vitro against Enterobacteriaceae isolated from intra-abdominal sites, including ESBL-producing organisms</dc:description>
<dc:creator>Pérez, J. L</dc:creator>
<dc:creator>Cercenado, E</dc:creator>
<dc:creator>Rubio, C</dc:creator>
<dc:creator>Zinder, T. A</dc:creator>
<dc:creator>Sanz-Rodríguez, C</dc:creator>
<dc:creator>Gobernado, M</dc:creator>
<dc:creator>Cisterna, R</dc:creator>
<dc:creator>Pascual, A</dc:creator>
<dc:creator>García-Rodríguez, J. A</dc:creator>
<dc:creator>Manchado, P</dc:creator>
<dc:creator>Rosa, M. de la</dc:creator>
<dc:creator>Prats, G</dc:creator>
<dc:creator>Martín, R</dc:creator>
<dc:creator>Baquero, F</dc:creator>
<dc:creator>Picazo, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El estudio SMART ( Study for Monitoring Antimicrobial Resistance Trends ) es un programa mundial de vigilancia de la resistencia a los antimicrobianos de microorganismos aislados de infecciones intraabdominales. En este subanálisis se evaluó el patrón de sensibilidad de las enterobacterias recogidas en los 13 centros españoles participantes en el año 2003. Se determinaron las CMI de diferentes antimicrobianos por el método de microdilución en caldo siguiendo las recomendaciones del CLSI (antes NCCLS). Se confirmó la presencia de betalactamasas de espectro extendido (BLEE) en aquellas cepas frente a las cuales las CMI de ceftriaxona, ceftazidima y cefepima eran &amp;#8805;2 mg/l mediante la comparación de las CMI de cefepima con o sin ácido clavulánico (10 mg/l). Se evaluaron 981 enterobacterias de 840 pacientes. De ellas, 398 (41%) eran de adquisición comunitaria. Escherichia coli fue el aislamiento más frecuente (571 cepas; 58%), seguida por Klebsiella        spp. (153 cepas; 16%), Enterobacter spp. (97 cepas; 10%) y Proteus spp. (63 cepas; 6%). Un total de 191 cepas procedentes de 176 pacientes eran productoras de betalactamasas inducibles (19%). Los carbapenémicos y la amikacina fueron los antibióticos más activos frente        a las enterobacterias (sensibilidad &amp;#8805;99%). La resistencia a ceftazidima, ciprofloxacino y levofloxacino fue superior al 10%. Se detectaron BLEE fenotípicamente en 61 (6%) de los aislamientos, siendo más frecuentes en E. coli (61%), Klebsiella spp. (20%) y Enterobacter spp. (8%). La resistencia entre las enterobacterias aisladas de infecciones intraabdominales constituye un problema en España. Una proporción significativa de las productoras de BLEE o de betalactamasas inducibles proceden de la comunidad. Los carbapenémicos ertapenem, imipenem y meropenem, y el aminoglucósido amikacina, son muy activos in vitro frente a las enterobacterias aisladas de focos intraabdominales, incluyendo aquéllas productoras de BLEE</dc:description>
<dc:source>Rev Esp Quimioter;19(1): 51-59, mar. 2006. tab, graf</dc:source>
<dc:identifier>ibc-047277</dc:identifier>
<dc:title xml:lang="es">Patrones de sensibilidad a antimicrobianos de Enterobacteriaceae causantes de infecciones intraabdominales en España: resultados del estudio SMART 2003</dc:title>
<dc:subject>^d10728^s22046</dc:subject>
<dc:subject>^d29640</dc:subject>
<dc:subject>^d7^s22080</dc:subject>
<dc:subject>^d911^s22011</dc:subject>
<dc:subject>^d911^s22078</dc:subject>
<dc:subject>^d5346^s22046</dc:subject>
<dc:subject>^d7^s22046</dc:subject>
<dc:subject>^d4836^s22080</dc:subject>
<dc:subject>^d1639^s22044</dc:subject>
<dc:subject>^d32383^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d4835^s22021</dc:subject>
<dc:subject>^d28460</dc:subject>
<dc:subject>^d13411^s22080</dc:subject>
<dc:subject>^d24244</dc:subject>
<dc:subject>^d5</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d911^s22000</dc:subject>
<dc:subject>^d4835^s22001</dc:subject>
<dc:subject>^d4836^s22046</dc:subject>
<dc:subject>^d32383^s22046</dc:subject>
<dc:subject>^d4835^s22026</dc:subject>
<dc:subject>^d32344</dc:subject>
<dc:subject>^d36322</dc:subject>
<dc:subject>^d36323</dc:subject>
<dc:subject>^d10728^s22080</dc:subject>
<dc:type>article</dc:type>
<dc:date>200603</dc:date>
</metadata>
</record>
</ibecs-document>
